The RCN-rabies constructs were highly protective and not significantly different from each other. Bats from the RCN- luc and topically vaccinated RCN-MoG groups did not have measurable antibody responses. Prior to challenge, 90% of RCN-G and 75% of RCN-MoG oronasally vaccinated bats had detectable levels of serum rabies neutralizing antibodies. Bats were vaccinated either oronasally (RCN-G, RCN-MoG) with 5x10 7 PFU or by topical application in glycerin jelly (RCN-MoG, dose 2x10 8 PFU), boosted (same dose and route) at 46 days post vaccination (dpv), and then challenged with wild-type big brown variant RABV at 65 dpv. No significant difference in antibody titers or survival was noted between rabies-vaccinated groups. Mice vaccinated and boosted intradermally with 1 x 10 7 plaque forming units (PFU) of each RCN-rabies vaccine construct developed neutralizing antibodies and survived at significantly higher rates than controls.
This sequence, which represents strains more likely to occur in bats, was cloned into raccoonpox virus (RCN) and the efficacy of this novel RCN-MoG vaccine was compared to RCN-G that expresses the glycoprotein gene from CVS-11 rabies or luciferase (RCN- luc, negative control) in mice and big brown bats ( Eptesicus fuscus).
In order to develop a new vaccine for potential use in bats, a reservoir of rabies infection for humans and animals alike, an in silico antigen designer tool was used to create a mosaic glycoprotein (MoG) gene using available sequences from the rabies Phylogroup I glycoprotein. Rabies is an ancient neglected tropical disease that causes tens of thousands of human deaths and millions of cattle deaths annually.